IND. SWIFT | CIPLA | IND. SWIFT/ CIPLA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -1.9 | 30.8 | - | View Chart |
P/BV | x | - | 4.3 | - | View Chart |
Dividend Yield | % | 0.0 | 0.5 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
IND. SWIFT Mar-21 |
CIPLA Mar-21 |
IND. SWIFT/ CIPLA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 5 | 879 | 0.6% | |
Low | Rs | 2 | 411 | 0.5% | |
Sales per share (Unadj.) | Rs | 65.7 | 237.6 | 27.7% | |
Earnings per share (Unadj.) | Rs | -5.5 | 29.8 | -18.5% | |
Cash flow per share (Unadj.) | Rs | 0.5 | 43.0 | 1.2% | |
Dividends per share (Unadj.) | Rs | 0 | 5.00 | 0.0% | |
Avg Dividend yield | % | 0 | 0.8 | 0.0% | |
Book value per share (Unadj.) | Rs | -128.4 | 226.7 | -56.6% | |
Shares outstanding (eoy) | m | 54.16 | 806.46 | 6.7% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 0.1 | 2.7 | 1.9% | |
Avg P/E ratio | x | -0.6 | 21.6 | -2.9% | |
P/CF ratio (eoy) | x | 6.4 | 15.0 | 42.6% | |
Price / Book Value ratio | x | 0 | 2.8 | -0.9% | |
Dividend payout | % | 0 | 16.8 | 0.0% | |
Avg Mkt Cap | Rs m | 184 | 519,826 | 0.0% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 512 | 32,518 | 1.6% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 3,561 | 191,596 | 1.9% | |
Other income | Rs m | 152 | 2,698 | 5.6% | |
Total revenues | Rs m | 3,713 | 194,294 | 1.9% | |
Gross profit | Rs m | 402 | 42,487 | 0.9% | |
Depreciation | Rs m | 327 | 10,677 | 3.1% | |
Interest | Rs m | 522 | 1,607 | 32.5% | |
Profit before tax | Rs m | -295 | 32,901 | -0.9% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 3 | 8,888 | 0.0% | |
Profit after tax | Rs m | -298 | 24,013 | -1.2% | |
Gross profit margin | % | 11.3 | 22.2 | 50.9% | |
Effective tax rate | % | -1.1 | 27.0 | -4.1% | |
Net profit margin | % | -8.4 | 12.5 | -66.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 2,652 | 132,095 | 2.0% | |
Current liabilities | Rs m | 7,062 | 45,916 | 15.4% | |
Net working cap to sales | % | -123.9 | 45.0 | -275.3% | |
Current ratio | x | 0.4 | 2.9 | 13.1% | |
Inventory Days | Days | 153 | 68 | 226.3% | |
Debtors Days | Days | 1,107 | 7 | 16,857.6% | |
Net fixed assets | Rs m | 4,064 | 116,277 | 3.5% | |
Share capital | Rs m | 108 | 1,613 | 6.7% | |
"Free" reserves | Rs m | -7,060 | 181,232 | -3.9% | |
Net worth | Rs m | -6,952 | 182,844 | -3.8% | |
Long term debt | Rs m | 6,442 | 12,028 | 53.6% | |
Total assets | Rs m | 6,716 | 248,372 | 2.7% | |
Interest coverage | x | 0.4 | 21.5 | 2.0% | |
Debt to equity ratio | x | -0.9 | 0.1 | -1,408.7% | |
Sales to assets ratio | x | 0.5 | 0.8 | 68.7% | |
Return on assets | % | 3.3 | 10.3 | 32.3% | |
Return on equity | % | 4.3 | 13.1 | 32.7% | |
Return on capital | % | -44.5 | 17.7 | -251.2% | |
Exports to sales | % | 74.2 | 31.3 | 237.2% | |
Imports to sales | % | 5.0 | 10.9 | 45.4% | |
Exports (fob) | Rs m | 2,643 | 59,951 | 4.4% | |
Imports (cif) | Rs m | 176 | 20,911 | 0.8% | |
Fx inflow | Rs m | 2,682 | 68,051 | 3.9% | |
Fx outflow | Rs m | 260 | 20,911 | 1.2% | |
Net fx | Rs m | 2,422 | 47,140 | 5.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 772 | 37,552 | 2.1% | |
From Investments | Rs m | -167 | -23,872 | 0.7% | |
From Financial Activity | Rs m | -483 | -13,299 | 3.6% | |
Net Cashflow | Rs m | 122 | 509 | 24.0% |
Indian Promoters | % | 55.6 | 13.5 | 412.0% | |
Foreign collaborators | % | 0.0 | 20.1 | - | |
Indian inst/Mut Fund | % | 0.0 | 48.6 | - | |
FIIs | % | 0.0 | 26.6 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 44.4 | 66.4 | 66.9% | |
Shareholders | 14,009 | 418,584 | 3.3% | ||
Pledged promoter(s) holding | % | 73.4 | 0.0 | - |
Compare IND. SWIFT With: SUN PHARMA LUPIN DR. REDDYS LAB ZYDUS LIFESCIENCES AUROBINDO PHARMA
Bulls marked a strong comeback today as Indian share markets ended nearly 3% higher. After opening the day higher, equity markets extended gains as the session progressed and ended near the day's high.
The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?
As the new variant of Covid-19 emerges, keep an eye on these stocks.
These companies are likely to benefit the most from Covid-19 vaccines.
The stock fell 3.5% even as the company reported numbers higher than analysts' expectations.
During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.
More Views on NewsWe are just two months into 2022 and several penny stocks that we track have already surged 5x.
Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.
A step-by-step method to pick the best penny stocks for the long term.
These penny stocks can become future multibaggers. Watch out for them.
Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?
More